Why This Bullishly Ranked Biotech Stock Just Broke Out To A Record High [Investor's Business Daily]
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: Investors Business Daily
Related news Shares of Syndax Pharmaceuticals ( SNDX ) soared to a record high Tuesday after the biotech company unveiled promising results for its early-stage blood cancer treatment. Syndax stock jumped more than 50% on the news. Syndax tested its drug, dubbed SNDX-5613, in a total of six patients with hard-to-treat acute leukemia. The cancer treatment works by disrupting the interaction between a protein called menin and a gene known as MLL1. Of those six, three had rearrangements of the MLL1 gene. One of those patients achieved a complete response, while a second partially responded to the cancer treatment, Syndax said in a news release. The third didn't receive sufficient drug exposure to respond. In general, these leukemia patients have a poor prognosis, Chief Executive Briggs Morrison said in a written statement. Their cancer has either relapsed or is refractory, meaning it resists other cancer treatments. "Notably, clinical activity was achieved rapidly after a single, 28-day c
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Syndax Pharmaceuticals (SNDX) had its price target raised by Citigroup Inc. from $51.00 to $57.00. They now have a "buy" rating on the stock.MarketBeat
- Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs [Yahoo! Finance]Yahoo! Finance
- Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? [Yahoo! Finance]Yahoo! Finance
- Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
SNDX
Earnings
- 2/26/26 - Miss
SNDX
Sec Filings
- 2/26/26 - Form S-8
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- SNDX's page on the SEC website